Trastuzumab emtansine (T-DM1) plus capecitabine (X) in patients with HER2-positive MBC: MO28230 TRAX-HER2 phase 1 results.
Karen A. Gelmon(University of British Columbia), Véronique Dièras(Institut Curie), Marie‐Paule Sablin(Institut Curie), Diego Villa(BC Cancer Agency), Jesús Soberino(Hospital Quirónsalud Barcelona), Javier Cortés(Villa Maria Hospital), Charlotte Colthorpe(Roche (Switzerland)), Rosanne Serpanchy(BC Cancer Agency), Mustapha Zoubir(Institut Curie), María Vidal(Inserm), Ulrich Freudensprung(Merck Serono (Switzerland)), Jian Xu(University of California, Los Angeles)
Cited by 4
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k